Health Catalyst Inc. Insider Trading

HCAT

Last 12 months

Insiders bought 106K and sold 201K on the open market.

36% of the selling was scheduled in advance under 10b5-1 plans. Director Julie Larson-Green sold 128K on Dec 4, 2025, 39% of their stake, outside a plan.

Net open-market

−95K

1 buy · 2 sales

Under a 10b5-1 plan

36%

of the value sold

Insiders who bought / sold

1 / 2

executives and directors

Last open-market buy

Sep 2026

Sep 14, 2026

Get an email when HCAT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 14	Simeon Kohl Chief Executive Officer	Bought	59,000	$1.79	106K	2.1%	Form 4
Dec 5, 2025	Benjamin Landry General Counsel	Sold10b5-1 plan	27,425	$2.64	72K	22%	Form 4
Dec 4, 2025	Julie Larson-Green Director	SoldNo plan	47,997	$2.67	128K	39%	Form 4
Sep 5, 2025	Benjamin Landry General Counsel	Sold10b5-1 plan	6,175	$3.35	21K	4.2%	Form 4
Jun 5, 2025	Benjamin Landry General Counsel	Sold10b5-1 plan	6,057	$3.94	24K	3.9%	Form 4
May 5, 2025	Daniel Lesueur Chief Operating Officer	Sold10b5-1 plan	5,209	$4.10	21K	2.5%	Form 4
Apr 3, 2025	Daniel Lesueur Chief Operating Officer	Sold10b5-1 plan	5,209	$4.15	22K	2.4%	Form 4
Mar 6, 2025	Benjamin Landry General Counsel	Sold10b5-1 plan	13,827	$4.55	63K	7.9%	Form 4
Mar 5, 2025	Daniel Lesueur Chief Operating Officer	Sold10b5-1 plan	16,902	$4.52	76K	7.2%	Form 4
Feb 18, 2025	Linda Llewelyn Chief People Officer	Sold10b5-1 plan	6,441	$5.43	35K	7.0%	Form 4
Feb 5, 2025	Daniel Lesueur Chief Operating Officer	Sold10b5-1 plan	5,209	$5.76	30K	5.7%	Form 4
Jan 15, 2025	Linda Llewelyn Chief People Officer	Sold10b5-1 plan	6,442	$5.80	37K	6.5%	Form 4
Jan 6, 2025	Daniel Lesueur Chief Operating Officer	Sold10b5-1 plan	5,209	$7.51	39K	5.4%	Form 4
Jan 6, 2025	Benjamin Landry General Counsel	Sold10b5-1 plan	2,500	$7.52	19K	3.3%	Form 4
Dec 30, 2024	Duncan Gallagher Director	Sold10b5-1 plan	4,500	$6.93	31K	6.0%	Form 4
Dec 23, 2024	Duncan Gallagher Director	Sold10b5-1 plan	4,500	$6.98	31K	5.7%	Form 4
Dec 16, 2024	Linda Llewelyn Chief People Officer	Sold10b5-1 plan	6,442	$7.88	51K	6.1%	Form 4
Dec 6, 2024	Jason Alger Chief Financial Officer	Sold10b5-1 plan	19,599	$8.32	163K	18%	Form 4
Dec 6, 2024	Benjamin Landry General Counsel	Sold10b5-1 plan	19,268	$8.32	160K	21%	Form 4
Dec 4, 2024	Daniel Lesueur Chief Operating Officer	Sold10b5-1 plan	22,773	$7.70	175K	19%	Form 4
Dec 2, 2024	Kevin Lee Freeman Chief Commercial Officer	Sold10b5-1 plan	7,500	$8.94	67K	3.1%	Form 4
Nov 15, 2024	Linda Llewelyn Chief People Officer	Sold10b5-1 plan	1,365	$8.50	12K	1.2%	Form 4

Sep 14
Simeon Kohl
Chief Executive Officer · bought 59,000 at $1.79
106K
2.1% of stake
Dec 5, 202510b5-1 plan
Benjamin Landry
General Counsel · sold 27,425 at $2.64
72K
22% of stake
Dec 4, 2025No plan
Julie Larson-Green
Director · sold 47,997 at $2.67
128K
39% of stake
Sep 5, 202510b5-1 plan
Benjamin Landry
General Counsel · sold 6,175 at $3.35
21K
4.2% of stake
Jun 5, 202510b5-1 plan
Benjamin Landry
General Counsel · sold 6,057 at $3.94
24K
3.9% of stake
May 5, 202510b5-1 plan
Daniel Lesueur
Chief Operating Officer · sold 5,209 at $4.10
21K
2.5% of stake
Apr 3, 202510b5-1 plan
Daniel Lesueur
Chief Operating Officer · sold 5,209 at $4.15
22K
2.4% of stake
Mar 6, 202510b5-1 plan
Benjamin Landry
General Counsel · sold 13,827 at $4.55
63K
7.9% of stake
Mar 5, 202510b5-1 plan
Daniel Lesueur
Chief Operating Officer · sold 16,902 at $4.52
76K
7.2% of stake
Feb 18, 202510b5-1 plan
Linda Llewelyn
Chief People Officer · sold 6,441 at $5.43
35K
7.0% of stake
Feb 5, 202510b5-1 plan
Daniel Lesueur
Chief Operating Officer · sold 5,209 at $5.76
30K
5.7% of stake
Jan 15, 202510b5-1 plan
Linda Llewelyn
Chief People Officer · sold 6,442 at $5.80
37K
6.5% of stake
Jan 6, 202510b5-1 plan
Daniel Lesueur
Chief Operating Officer · sold 5,209 at $7.51
39K
5.4% of stake
Jan 6, 202510b5-1 plan
Benjamin Landry
General Counsel · sold 2,500 at $7.52
19K
3.3% of stake
Dec 30, 202410b5-1 plan
Duncan Gallagher
Director · sold 4,500 at $6.93
31K
6.0% of stake
Dec 23, 202410b5-1 plan
Duncan Gallagher
Director · sold 4,500 at $6.98
31K
5.7% of stake
Dec 16, 202410b5-1 plan
Linda Llewelyn
Chief People Officer · sold 6,442 at $7.88
51K
6.1% of stake
Dec 6, 202410b5-1 plan
Jason Alger
Chief Financial Officer · sold 19,599 at $8.32
163K
18% of stake
Dec 6, 202410b5-1 plan
Benjamin Landry
General Counsel · sold 19,268 at $8.32
160K
21% of stake
Dec 4, 202410b5-1 plan
Daniel Lesueur
Chief Operating Officer · sold 22,773 at $7.70
175K
19% of stake
Dec 2, 202410b5-1 plan
Kevin Lee Freeman
Chief Commercial Officer · sold 7,500 at $8.94
67K
3.1% of stake
Nov 15, 202410b5-1 plan
Linda Llewelyn
Chief People Officer · sold 1,365 at $8.50
12K
1.2% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch HCAT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Services-Computer Programming, Data Processing, Etc. · Pick stocks to compare with HCAT

CompareIntrinsic value

PUBMPubMatic Inc.

$16.36+1.30%52

SMWBSimilarweb Ltd.

$8.81+0.69%46

SOGPSound Group Inc.

$10.51-2.23%85

EBEventbrite, Inc.

No recent price68

NXDRNextdoor Holdings, Inc.

$2.44+5.17%57

HSTMHealthStream Inc.

$32.48+2.56%71

YALAYalla Group Ltd

$5.64+1.81%79

SSTSystem1 Inc.

$1.76-0.56%25

Held by ETFs

HCAT is in 5 US ETFs. The largest of them, with HCAT's weight in each:

Spot a number that looks wrong? Check it in HCAT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing HCAT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.